PainChek Ltd
PainChek Limited is an Australia-based company which develops pain assessment technologies.
The business
PainChek Limited is an Australia-based company which develops pain assessment technologies. The Company's principal activities are development and commercialization of mobile medical device applications that provide pain assessment for individuals that are unable to communicate with their carers. Its segments include Infant App (in Australia), and Adult App in Australia and New Zealand (ANZ), the United Kingdom (UK) and North America. The Company's PainChek Universal is a complete point-of-care solution that combines the existing PainChek Application with the numerical rating scale (NRS). PainChek Application uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalize pain, whilst also driving objectivity and consistency in all assessments. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.
Small Caps Research
No research on PainChek Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise PCK based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
PainChek Inks Landmark 20,000-Bed North America Deployment with Sabra Health Care REIT
PainChek inks landmark 20,000-bed North American deployment with Sabra Health Care REIT across 329 facilities, funding beds at $55-75/bed/yr.
PainChek partners with Eldermark Software to expand US market for smartphone pain assessment app
Smartphone pain assessment app developer PainChek (ASX: PCK) has signed a new reseller and integration agreement with Minneapolis-based assisted living provider Eldermark Software to help expand its US market reach. Under the terms of the 12-month rolling agreement, Eldermark will act as a non-exclusive reseller of PainChek’s Adult phone app targeting the US long-term residential […]
PainChek prepares FDA De Novo submission for smartphone app following successful US clinical study
PainChek (ASX: PCK) has announced positive outcomes from a US clinical validation study that will allow the company to progress with a Food and Drug Administration (FDA) De Novo submission for its Adult smartphone app. The study recruited 105 nursing home residents at five sites in Iowa and New York, who were assessed for pain […]
Residential aged care sector drives strong quarterly results for PainChek
Australian medical device company PainChek (ASX: PCK) has reported a strong performance for the March quarter with much of its growth being driven by the country’s residential aged care sector. PainChek’s smartphone-based pain assessment technology was contracted to 49,811 residential aged care and dementia-specific beds during the quarter, representing a 56% increase on the 32,023 […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.